Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius subsp. salicinius AP-32 + lactobacillus plantarum LPL28 + lactobacillus paracasei ET-66
- Development stage
- Unknown
- Lead developer
- Bioflag Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PE0301 is a postbiotic formulation developed by Glac Biotech and marketed by Bioflag Biotech, consisting of heat-inactivated cells and fermentation metabolites from three specific probiotic strains: *Lactobacillus salivarius* subsp. *salicinius* AP-32, *Lactobacillus plantarum* LPL28, and *Lactobacillus paracasei* ET-66. Unlike traditional probiotics, this product contains inanimate bacterial components and cell-free supernatants rather than live organisms. It is primarily indicated for oral health, where it functions by inhibiting oral pathogens such as *Streptococcus mutans*, modulating the oral microbiota, and enhancing salivary immunity through the induction of salivary immunoglobulin A (sIgA). The formulation has demonstrated antimicrobial activity and safety in preclinical and clinical evaluations and is typically delivered as oral lozenges or powder.
- Other names
- PE0301PE-0301PE 0301AP-32 + LPL28 + ET-66 postbiotic
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on lactobacillus salivarius subsp. salicinius AP-32 + lactobacillus plantarum LPL28 + lactobacillus paracasei ET-66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius subsp. salicinius AP-32 + lactobacillus plantarum LPL28 + lactobacillus paracasei ET-66.